LIBERTY 2: An international phase 3 randomized, double-blind, placebo-controlled efficacy and safety study to evaluate relugolix co administered with and without low-dose estradiol and norethindrone acetate in women with heavy menstrual bleeding associated with uterine fibroids
An international phase 3 randomized, double-blind, placebo-controlled efficacy and safety study to evaluate relugolix administered with and without low-dose estradiol and norethindrone acetate in women with endometriosis-associated pain
A phase 3, randomized, parallel-group, multicenter, open-label, pharmacokinetic, noninferiority study of ravulizumab administered subcutaneously versus intravenously in adult patients with paroxysmal nocturnal hemoglobinuria currently treated with eculizumab
Randomized phase 3 study evaluating the efficacy and the safety of oral azacitidine (CC-486) compared to investigator’s choice therapy in patient with relapsed or refractory angioimmunoblastic T- cell lymphoma
A phase 1b open-label study assessing the pharmacokinetics, tolerability, and safety of oral trimetazidine in subjects with acute-on-chronic liver failure - trust: trimetazidine for acute on chronic liver failure study
A phase 4, double-blind, randomized, placebo-controlled study evaluating the pharmacokinetics and safety of obeticholic acid in patients with primary biliary cholangitis and moderate to severe hepatic impairment
A first-time-in human (FTIH), Phase I, randomized,multi-centric, single-blind, controlled dose-escalation study to evaluate the reactogenicity, safety, immunogenicity and efficacy of GSK Biologicals’ HBV viral vector vaccines given in a prime-boost schedule with sequential or co-administration of adjuvanted proteins therapeutic vaccine (GSK3528869A) in chronic Hepatitis B patients (18-65 years old) well controlled under nucleo(s)tides analogues (NA) therapy.